TY - JOUR
T1 - Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years
AU - Garbe, Claus
AU - Keim, Ulrike
AU - Amaral, Teresa
AU - Ascierto, Paolo A.
AU - Bauer, Jürgen
AU - Dummer, Reinhard
AU - Eggermont, Alexander M.M.
AU - Eigentler, Thomas K.
AU - Flatz, Lukas
AU - Forchhammer, Stephan
AU - Forschner, Andrea
AU - Gandini, Sara
AU - Gershenwald, Jeffrey E.
AU - Hauschild, Axel
AU - Hoeller, Christoph
AU - Kirkwood, John M.
AU - Lebbe, Celeste
AU - Long, Georgina V.
AU - Lorigan, Paul
AU - Luke, Jason J.
AU - Meier, Friedegund
AU - Metzler, Gisela
AU - Nathan, Paul
AU - Postow, Michael A.
AU - Robert, Caroline
AU - Röcken, Martin
AU - Schadendorf, Dirk
AU - Weide, Benjamin
AU - Whiteman, David
AU - Leiter, Ulrike
AU - Martus, Peter
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026/12
Y1 - 2026/12
N2 - A false-negative diagnosis of cancer can lead to a delay in effective treatment and a poorer prognosis. Here, we use the example of cutaneous melanoma to examine how many years of life are lost after a false-negative diagnosis compared to a primarily correct diagnosis. From 1996 to 2015, 9,063 patients are prospectively registered in the German Central Malignant Melanoma Registry and followed up until December 2023. A false-negative diagnosis is found in 206 (2.3%) patients. The median time to correct diagnosis is 24.0 months. The 10-year recurrence-free survival probabilities are 32.9% for false-negative diagnoses and 76.2% for correct diagnoses (p < 0.001). The 10-year melanoma-specific survival probabilities are 62.1% versus 85.0% (p < 0.001). On average, each person with an initial false-negative diagnosis loses 8.2 years of life compared to people with a correct diagnosis. This high number of years of life lost raises the question of whether similar results also apply to other types of cancer.
AB - A false-negative diagnosis of cancer can lead to a delay in effective treatment and a poorer prognosis. Here, we use the example of cutaneous melanoma to examine how many years of life are lost after a false-negative diagnosis compared to a primarily correct diagnosis. From 1996 to 2015, 9,063 patients are prospectively registered in the German Central Malignant Melanoma Registry and followed up until December 2023. A false-negative diagnosis is found in 206 (2.3%) patients. The median time to correct diagnosis is 24.0 months. The 10-year recurrence-free survival probabilities are 32.9% for false-negative diagnoses and 76.2% for correct diagnoses (p < 0.001). The 10-year melanoma-specific survival probabilities are 62.1% versus 85.0% (p < 0.001). On average, each person with an initial false-negative diagnosis loses 8.2 years of life compared to people with a correct diagnosis. This high number of years of life lost raises the question of whether similar results also apply to other types of cancer.
UR - https://www.scopus.com/pages/publications/105043570606
U2 - 10.1038/s41467-026-74443-9
DO - 10.1038/s41467-026-74443-9
M3 - Article
AN - SCOPUS:105043570606
SN - 2041-1723
VL - 17
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 5790
ER -